Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBiondetti, Emma
dc.contributor.authorSantin, Mathieu
dc.contributor.authorValabrègue, Romain
dc.contributor.authorMangone, Graziella
dc.contributor.authorGaurav, Rahul
dc.contributor.authorPyatigorskaya, Nadya
dc.contributor.authorVila Bover, Miquel
dc.date.accessioned2022-06-14T07:44:29Z
dc.date.available2022-06-14T07:44:29Z
dc.date.issued2021-10
dc.identifier.citationBiondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, et al. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease. Brain. 2021 Oct;144(10):3114–25.
dc.identifier.issn1460-2156
dc.identifier.urihttps://hdl.handle.net/11351/7678
dc.descriptionDopamine transporter; Iron; Neuromelanin
dc.description.abstractIn Parkinson’s disease, there is a progressive reduction in striatal dopaminergic function, and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition in the substantia nigra. We tested the hypothesis of a relationship between impairment of the dopaminergic system and changes in the iron metabolism. Based on imaging data of patients with prodromal and early clinical Parkinson’s disease, we assessed the spatiotemporal ordering of such changes and relationships in the sensorimotor, associative and limbic territories of the nigrostriatal system. Patients with Parkinson’s disease (disease duration < 4 years) or idiopathic REM sleep behaviour disorder (a prodromal form of Parkinson’s disease) and healthy controls underwent longitudinal examination (baseline and 2-year follow-up). Neuromelanin and iron sensitive MRI and dopamine transporter single-photon emission tomography were performed to assess nigrostriatal levels of neuromelanin, iron, and dopamine. For all three functional territories of the nigrostriatal system, in the clinically most and least affected hemispheres separately, the following was performed: cross-sectional and longitudinal intergroup difference analysis of striatal dopamine and iron, and nigral neuromelanin and iron; in Parkinson’s disease patients, exponential fitting analysis to assess the duration of the prodromal phase and the temporal ordering of changes in dopamine, neuromelanin or iron relative to controls; and voxel-wise correlation analysis to investigate concomitant spatial changes in dopamine-iron, dopamine-neuromelanin and neuromelanin-iron in the substantia nigra pars compacta. The temporal ordering of dopaminergic changes followed the known spatial pattern of progression involving first the sensorimotor, then the associative and limbic striatal and nigral regions. Striatal dopaminergic denervation occurred first followed by abnormal iron metabolism and finally neuromelanin changes in the substantia nigra pars compacta, which followed the same spatial and temporal gradient observed in the striatum but shifted in time. In conclusion, dopaminergic striatal dysfunction and cell loss in the substantia nigra pars compacta are interrelated with increased nigral iron content.
dc.language.isoeng
dc.publisherOxford University Press
dc.relation.ispartofseriesBrain;144(10)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectParkinson, Malaltia de - Imatgeria per ressonància magnètica
dc.subjectNeurones dopaminèrgiques
dc.subject.meshParkinson Disease
dc.subject.mesh/diagnostic imaging
dc.subject.meshMelanins
dc.subject.meshDopamine
dc.titleThe spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson’s disease
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1093/brain/awab191
dc.subject.decsenfermedad de Parkinson
dc.subject.decs/diagnóstico por imagen
dc.subject.decsmelaninas
dc.subject.decsdopamina
dc.relation.publishversionhttps://doi.org/10.1093/brain/awab191
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Biondetti E, Gaurav R] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France. ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France. [Santin MD, Valabrègue R] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. ICM, Centre de NeuroImagerie de Recherche - CENIR, Paris, France. [Mangone G] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, Paris, France. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Paris, France. [Pyatigorskaya N] Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, Paris, France. ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), Paris, France. Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neuroradiology, Paris, France. [Vila M] Grup de Recerca en Malalties Neurodegeneratives, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED). Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
dc.identifier.pmid33978742
dc.identifier.wos000733375400026
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record